Novartis | NVS - Sales Revenues



Novartis reported $14.84B in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
AbbVie USD 15.42B 2.08B Jun/2025
Amgen USD 9.18B 1.03B Jun/2025
AstraZeneca USD 14.46B 867M Jun/2025
Bausch Health Companies USD 2.53B 270M Jun/2025
Biogen USD 2.6B 170M Jun/2025
Bristol-Myers Squibb USD 12.27B 1.07B Jun/2025
Canopy Growth CAD 72.13M 2.63M Jun/2025
Corcept Therapeutics USD 194.4M 37.2M Jun/2025
Drreddys Laboratories INR 85.45B 1.87B Jun/2025
Eli Lilly USD 15.56B 2.83B Jun/2025
Gilead Sciences USD 7.1B 430M Jun/2025
GlaxoSmithKline GBP 7.99B 470M Jun/2025
Glaxosmithkline GBP 7.99B 131M Jun/2025
J&J USD 23.74B 1.85B Jun/2025
Merck USD 15.81B 280M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Novartis USD 14.84B 1.28B Jun/2025
Pacira USD 181.1M 12.18M Jun/2025
Perrigo USD 1.06B 20M Jun/2025
Pfizer USD 14.7B 980M Jun/2025
Prestige Brands USD 249.53M 46.99M Jun/2025
Roche Holding CHF 31.64B 883M Dec/2024
Sanofi EUR 9.99B 90M Jun/2025
Sanofi EUR 10.74B 529.51M Jun/2025
Supernus Pharmaceuticals USD 165.5M 15.7M Jun/2025
Zoetis USD 2.46B 240M Jun/2025